THE USE OF SEMAGLUTIDE IN THE TREATMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS

Authors

  • Luiza Braga Cabrera Universidade Brasil image/svg+xml
  • Lara Caroline Pateis da Silva Universidade Brasil image/svg+xml
  • Sérgio dos Santos Camargo Universidade Brasil image/svg+xml
  • Bruna Marçal Guidoti Eleuterio Instituto Racine

DOI:

https://doi.org/10.51891/rease.v9i10.11429

Keywords:

Semaglutida. Diabetes Tipo 2. Obesidade. Ozempic.

Abstract

This research aims to analyze and expose the advantages and disadvantages of using semaglutide in the treatment of obesity and type 2 Diabetes Mellitus, as well as its main side effects and its impact on patients' long-term health. This is a bibliographic review research, in which articles, periodicals, books and magazines were used to collect data, using Google Scholar as a data search engine. Obesity is currently a public health issue, a global and multifactorial disease, which causes accumulation of the fat layer, adipose tissue, and in many cases is accompanied by Type 2 Diabetes Mellitus. Type 2 Diabetes Mellitus is a consequence of a lack of insulin, that is, the inability of insulin to exert its effects adequately, being a disease related to metabolism. The use of semaglutide has gained prominence in pharmacology, given that the drug is effective in weight loss, and is also used in the treatment of Type 2 Diabetes Mellitus, being an analogue of GLP-1, which has an appetite-inhibiting action, as a result reducing glycemic levels, contributing to weight loss.

1969 1674

Downloads

Download data is not yet available.

Author Biographies

  • Luiza Braga Cabrera, Universidade Brasil

    Graduando em farmácia pela Universidade Brasil.

  • Lara Caroline Pateis da Silva, Universidade Brasil

    Graduando em farmácia pela Universidade Brasil. 

  • Sérgio dos Santos Camargo, Universidade Brasil

    Graduando em farmácia pela Universidade Brasil. 

  • Bruna Marçal Guidoti Eleuterio, Instituto Racine

    Especialista em gestão de drogaria- Instituto Racine. 

Published

2023-10-31

How to Cite

Cabrera, L. B., Silva, L. C. P. da, Camargo, S. dos S., & Eleuterio, B. M. G. (2023). THE USE OF SEMAGLUTIDE IN THE TREATMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS. Revista Ibero-Americana de Humanidades, Ciências E Educação, 9(10), 25-38. https://doi.org/10.51891/rease.v9i10.11429

Most read articles by the same author(s)

Similar Articles

1-10 of 50

You may also start an advanced similarity search for this article.